The delay was made in order to provide the FDA more time to review and respond to information and materials that have been provided by Gen-Prob in connection with the Panel meeting and the Premarket Approval Application for the PROGENSA PCA3 Assay.
Gen-Probe informed DiagnoCure that it currently expects that the review could take place in the first quarter of 2012.